Contribute Try STAT+ Today

Amid growing anxiety over a lack of antibiotics, a new report from a Congressional watchdog found that the Department of Health and Human Services lacks an overarching strategy for developing new incentives to manufacturers.

In particular, the Government Accountability Office argued that the HHS so far hasn’t agreed about the need to offer certain types of so-called pull incentives, which could be offered to companies to help cover manufacturing and marketing costs after antibiotics have been approved by the Food and Drug Administration and reached the market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.